The National Institute for Allergy and Infectious Diseases has awarded Jeffrey Glenn, MD, PhD, professor of hepatology and gastroenterology and of microbiology and immunology, $69 million...
Read MoreA single dose of lambda-interferon reduced hospitalization among COVID-19 outpatients in a late-stage study spearheaded by a Stanford Medicine virologist.
Read MoreThe Antiviral Program for Pandemics (APP) aims to develop safe and effective antivirals to combat SARS-CoV-2, the virus that causes COVID-19, as well as to build sustainable platforms for targeted drug discovery and development of a robust pipeline of antivirals against viruses with pandemic potential.
Read MoreOriginally from Seoul, South Korea, Dr. Cho is a graduate of the University of California, Berkeley and Stanford University. Dr. Cho earned his doctorate in Chemical Engineering at Stanford under the guidance of Professor Curtis W. Frank. During his graduate studies, Dr. Cho first gained an interest in research at the interface of molecular virology and biomaterials. The principal goal of his thesis work was to develop lab-on-a-chip technologies for analysis of viral protein interactions with lipid membranes. Dr. Cho then continued his postdoctoral training in Professor Jeffrey S. Glenn's group in the Division of Gastroenterology and Hepatology at the Stanford University School of Medicine. He applied these engineering technologies to combat the hepatitis C virus (HCV), which affects over 170 million people worldwide. His work has led to significant advances for treating HCV, including new drugs currently in preclinical or clinical trials.
In addition, Dr. Cho has pioneered a novel approach to liver tissue engineering that has provided improved methods to study liver disease.In addition to his leadership of the Translational Science Group, Dr. Cho is active in the NTU community and serves as Deputy Director of the Nanyang Institute of Technology in Health and Medicine (NITHM) as well as Director of NTU's Research Experience for Undergraduates (REU) summer program in collaboration with the Asian Research Network. He is also a Principal Investigator at the Singapore- MIT Alliance for Research and Technology (SMART) and a Visiting Associate Professor at the Stanford University School of Medicine.
Dr. Cho's passion for translational and regenerative medicine has been recognized by several prestigious international honors and awards from the American Liver Foundation, Beckman Foundation, and leading global universities and companies including Chalmers University of Technology and Roche Ltd. In 2011, Dr. Cho was named an NRF Fellow by the Singapore National Research Foundation, and was also appointed to a Nanyang Associate Professorship. Dr. Cho is also the Founder of infollutionZERO, a global nonprofit organization committed to building a green digital world for future generations by raising awareness of infollution (information + pollution) in digital space and promoting digital literacy.
Dr. Edward Pham receives his MD and Ph.D in Microbiology & Immunology from Stanford University.
His research focus is on novel antiviral therapies for current and emerging viral infections and the relationship between chronic viral infection and cancer including liver cancer through studying how the innate and adaptive immune system are perturbed in chronic viral infection.
He has been recognized by many prestigious awards such as National Research Service Fellowship from NIH for MD/PhD, Gates Millenium Scholar, Howard Hughes Medical Institute, International Achievement Summit Delegate.
Dr. Mark Smith joined Stanford ChEM-H in May 2013 as the Head of the Medicinal Chemistry Knowledge Center. He graduated with a Ph.D. from the laboratory of Prof. Richard Stoodley at the University of Manchester Institute for Science and Technology (UMIST), where his research focused on the application of Lewis acid catalyzed hetero Diels-Alder reactions to the synthesis of novel disaccharide structures. In 2000, Dr.
Smith joined the research laboratory of Prof. David Crich at the University of Illinois at Chicago. Here his research focused on the generation of new reagents for the synthesis of beta-mannosides from thioglycosides. From 2002 to 2013, Dr. Smith worked as a medicinal chemist in Roche’s research facilities both in Palo Alto, CA and then Nutley, NJ, where he specialized in antiviral research.
Wendy is the CEO of IMI.AI, a company that allow doctors to give medical advice to patients seamlessly. Wendy has a proven executive management track record with almost ten years of experience in the healthcare and business industry. Wendy was previously Co-founder/CEO of Med2lab, a startup focuses on innovating medical training. The system got adopted by Stanford School of Medicine.
Before that, she spent 5 years in the Management Team at Marin General Hospital, working closely with the CEO, Lee Domanico, as her mentor. Wendy also acts as the President and Founder of Apollo Care, a 501(c)3 nonprofit organization that provides free healthcare support to poor children oversea. She’s also an alumni of Y Combinator founder track, one of the top incubators in the world.
Wendy attended Graduate program from the University of California, San Francisco and a Bachelor Degree in Psychology from UMass Amherst.